Skip to main content
. Author manuscript; available in PMC: 2009 May 6.
Published in final edited form as: Bioconjug Chem. 2008 Dec;19(12):2297–2299. doi: 10.1021/bc8004446

Figure 2.

Figure 2

Fluorescent microscope images of SKBR3 human breast cancer cells after pretargeting trastuzumab antibodies modified with rhodamine and norbornene and subsequent labeling with 3. (A) Rhodamine channel. (B) Near-IR channel (tetrazine-VT680). (C) Merged image of A and B. Images were also taken of cell surfaces targeted with a control antibody modified with only rhodamine and exposed subsequently to 3. (D) Rhodamine channel. (E) Near-IR channel.